GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Helius Medical Technologies Inc (NAS:HSDT) » Definitions » Change In Receivables

Helius Medical Technologies (Helius Medical Technologies) Change In Receivables : $-0.40 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Helius Medical Technologies Change In Receivables?

Helius Medical Technologies's change in receivables for the quarter that ended in Mar. 2024 was $0.07 Mil. It means Helius Medical Technologies's Accounts Receivable declined by $0.07 Mil from Dec. 2023 to Mar. 2024 .

Helius Medical Technologies's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.29 Mil. It means Helius Medical Technologies's Accounts Receivable increased by $0.29 Mil from Dec. 2022 to Dec. 2023 .

Helius Medical Technologies's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.05 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Helius Medical Technologies's Days Sales Outstanding for the three months ended in Mar. 2024 was 33.12.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Helius Medical Technologies's liquidation value for the three months ended in Mar. 2024 was $0.27 Mil.


Helius Medical Technologies Change In Receivables Historical Data

The historical data trend for Helius Medical Technologies's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helius Medical Technologies Change In Receivables Chart

Helius Medical Technologies Annual Data
Trend Mar14 Mar15 Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.72 0.22 - -0.10 -0.29

Helius Medical Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 -0.02 0.06 -0.50 0.07

Helius Medical Technologies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Helius Medical Technologies  (NAS:HSDT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Helius Medical Technologies's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.049/0.135*91
=33.12

2. In Ben Graham's calculation of liquidation value, Helius Medical Technologies's accounts receivable are only considered to be worth 75% of book value:

Helius Medical Technologies's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=3.638-3.771+0.75 * 0.049+0.5 * 0.739
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Helius Medical Technologies Change In Receivables Related Terms

Thank you for viewing the detailed overview of Helius Medical Technologies's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Helius Medical Technologies (Helius Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
642 Newtown Yardley Road, Suite 100, Newtown, PA, USA, 18940
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
Executives
Dane Andreeff director, 10 percent owner, officer: President and CEO C/O ANDREEFF EQUITY ADVISORS L.L.C., 140 E. ST. LUCIA LANE, SANTA ROSA BEACH FL 32459
Jeffrey S Mathiesen director, officer: CFO and Treasurer 43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Favit-van Pelt Antonella R. officer: Chief Medical Officer C/O HELIUS MEDICAL TECHNOLOGIES, INC., 642 NEWTOWN YARDLEY ROAD, NEWTOWN PA 18940
Paul Buckman director 12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Sherrie L Perkins director 5033 TANGLE LANE, HOUSTON TX 77056
Jennifer Laux officer: Chief Commercial Officer 642 NEWTOWN YARDLEY ROAD, SUITE 100, NEWTOWN PA 18940
Thomas E Griffin director C/O ENTELLUS MEDICAL, INC., 3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447
Blane Walter director 500 OLDE WORTHINGTON ROAD, WESTERVILLE OH 43082
Edward M Straw director C/O ESTEE LAUDER COMPANIES, 767 FIFTH AVENUE, NEW YORK NY 10153
Joyce N Laviscount officer: See Remarks 100 ENDO BOULEVARD, CHADDS FORD PA 19317
Huaizheng Peng director HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Philippe Deschamps director, 10 percent owner, officer: President & CEO 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Mitch E Tyler director HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Jonathan Sackier 10 percent owner, officer: Chief Medical Officer HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
A&b (hk) Co Ltd 10 percent owner 8/F BLDG A TONGFANG INFORMATION HARBOR, NO 11 LANGSHAN ROAD NANSHAN DISTRICT, SHENZHEN F4 518057

Helius Medical Technologies (Helius Medical Technologies) Headlines